Investigational Studies

brainPhoto Credit: Berkeley Lab In what is being heralded as a breakthrough for cancer research, GW Pharmaceuticals announced on Tuesday positive results from a study using a combination of cannabidiol and tetrahydrocannabinol to treat an aggressive form of brain cancer. Glioblastoma multiforme, or GBM is a “particularly aggressive brain tumor, with a poor prognosis,” according to the British-based biopharmaceutical […]

by

In what is being heralded as a breakthrough for cancer research, GW Pharmaceuticals announced on Tuesday positive results from a study using a combination of cannabidiol and tetrahydrocannabinol to treat an aggressive form of brain cancer. Glioblastoma multiforme, or GBM is a “particularly aggressive brain tumor, with a poor prognosis,” according to the British-based biopharmaceutical company focused on […]

by

In what is being heralded as a breakthrough for cancer research, GW Pharmaceuticals announced on Tuesday positive results from a study using a combination of cannabidiol and tetrahydrocannabinol to treat an aggressive form of brain cancer. Glioblastoma multiforme, or GBM is a “particularly aggressive brain tumor, with a poor prognosis,” according to the British-based biopharmaceutical company focused on […]

by

– Epidiolex® NDA submission process underway – – Conference call today at 4:30 p.m. EDT – LONDON and CARLSBAD, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces financial results […]

by

– Epidiolex® NDA submission process underway – – Conference call today at 4:30 p.m. EDT – LONDON and CARLSBAD, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces financial results […]

by

Top-line Phase 2 results for STAR 1 trial in epilepsy and STOP trial in osteoarthritis remain on track for reporting in August 2017 DEVON, Pa., Aug. 01, 2017 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal synthetic cannabinoid treatments, today reported financial results for […]

by

Top-line Phase 2 results for STAR 1 trial in epilepsy and STOP trial in osteoarthritis remain on track for reporting in August 2017 DEVON, Pa., Aug. 01, 2017 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal synthetic cannabinoid treatments, today reported financial results for […]

by

LONDON, July 24, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH), (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 7 August, 2017 its third quarter financial results for the period ending 30 June, 2017. GW will also host a […]

LONDON, July 24, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH), (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 7 August, 2017 its third quarter financial results for the period ending 30 June, 2017. GW will also host a […]

LONDON, April 18, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, noted that the American Academy of Neurology (AAN) issued a press release today announcing positive results from a second Phase 3 study […]

In order to use Medscape, your browser must be set to accept cookies delivered by the Medscape site. Medscape uses cookies to customize the site based on the information we collect at registration. The cookies contain no personally identifiable information and have no effect once you leave the Medscape site. … read more at: http://www.medscape.com/viewarticle/878883